RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 13
OP 14
DO 10.1177/1559897714568624
UL http://mdc.sagepub.com/content/14/55/13.abstract
AB Patients with myelodysplastic syndrome and chronic myelomonocytic leukemia, particularly those with high risk disease, have an unmet therapeutic need. Azacitidine monotherapy results in a modest response rate and duration of response. The addition of vorinostat or lenalidomide to azacytidine does not improve overall response rates, but may improve disease-free survival, does increase toxicity, discontinuations, and dose-reductions.